9 METERS BIOPHARMA, INC.

2019 Q1 Form 10-K Financial Statement

#000155198619000019 Filed on March 18, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q3 2018 Q2

Balance Sheet

Concept 2019 Q1 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.49M $8.110M $10.66M
YoY Change -11.48% 4670.59% 26550.0%
Cash & Equivalents $11.49M $8.112M $10.66M
Short-Term Investments
Other Short-Term Assets $980.0K $530.0K $240.0K
YoY Change 292.0% 103.85% -27.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.47M $8.637M $10.91M
YoY Change -5.7% 714.84% 816.62%
LONG-TERM ASSETS
Property, Plant & Equipment $29.96K $40.23K $45.37K
YoY Change -42.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K $5.580K
YoY Change 0.0% -44.2% -44.2%
Total Long-Term Assets $117.5K $45.81K $50.95K
YoY Change 104.25% -98.03% -97.84%
TOTAL ASSETS
Total Short-Term Assets $12.47M $8.637M $10.91M
Total Long-Term Assets $117.5K $45.81K $50.95K
Total Assets $12.59M $8.683M $10.96M
YoY Change -5.23% 156.14% 208.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.929M $2.883M $3.348M
YoY Change 94.01% 364.98% 458.87%
Accrued Expenses $897.3K $229.4K $0.00
YoY Change 15035.88% -84.81% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $3.740M $5.190M $4.150M
YoY Change 9.68% 276.09% 992.11%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.94M $8.302M $7.500M
YoY Change 101.22% 70.13% 99.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.00K
YoY Change
Total Long-Term Liabilities $30.00K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.94M $8.302M $7.500M
Total Long-Term Liabilities $30.00K $0.00 $0.00
Total Liabilities $10.97M $8.300M $7.500M
YoY Change 101.71% 70.08% 99.47%
SHAREHOLDERS EQUITY
Retained Earnings -$47.95M -$39.30M -$38.53M
YoY Change 39.74% 7.12%
Common Stock $3.107K $2.598K $2.570K
YoY Change 20.94% 157.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.618M $380.8K $3.459M
YoY Change
Total Liabilities & Shareholders Equity $12.59M $8.683M $10.96M
YoY Change -5.23% 156.14% 208.7%

Cashflow Statement

Concept 2019 Q1 2018 Q3 2018 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 innt Royalties Payment Expiration Requirement
RoyaltiesPaymentExpirationRequirement
P10Y
CY2018Q1 innt Saleof Stock Shares Issuable Upon Exerciseof Warrant
SaleofStockSharesIssuableUponExerciseofWarrant
2051771 shares
CY2018Q1 innt Saleof Stock Shelf Registration Maximum Equity Offering Price
SaleofStockShelfRegistrationMaximumEquityOfferingPrice
175000000 USD
CY2017 innt Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
0 USD
CY2018 innt Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
275000 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.193
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.030
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
10700 USD
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1588700 USD
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1677600 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q1 innt Saleof Stock Stockholders Aggregate Shares Availableforsale
SaleofStockStockholdersAggregateSharesAvailableforsale
13990403 shares
CY2018Q4 innt Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Discount Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountRate
0.131
CY2018 innt Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Discount Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountRate
0.136
CY2018 innt Stock Issued During Period Value Stock Splits
StockIssuedDuringPeriodValueStockSplits
-978674 USD
CY2018 innt Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
841026 USD
CY2017 innt Tax Cutsand Jobs Actof2017 Decreasein Valuation Allowance
TaxCutsandJobsActof2017DecreaseinValuationAllowance
2200000 USD
CY2018 innt Warrant Term
WarrantTerm
P5Y
CY2017 innt Warrants Issued To Placement Agents
WarrantsIssuedToPlacementAgents
0 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
865600 USD
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.014
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.009
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4336800 USD
CY2018 innt Warrants Issued To Placement Agents
WarrantsIssuedToPlacementAgents
913000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
15366100 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2658637 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3618634 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1180225 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
826327 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
3551900 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1400 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4500 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
224900 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6593 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26148 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7167189 USD
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42157122 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41985593 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39683119 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39854297 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3077887 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6018732 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3805000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2569659 USD
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.98
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2000000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1995000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6019000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3805000 USD
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
39525 USD
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2513475 USD
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6844979 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9031318 shares
CY2017Q4 us-gaap Assets
Assets
798489 USD
CY2018Q4 us-gaap Assets
Assets
6454188 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
752202 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6413513 USD
CY2017Q4 us-gaap Cash
Cash
355563 USD
CY2018Q4 us-gaap Cash
Cash
5728900 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360811 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
355563 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5728900 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5248 USD
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5373337 USD
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0 USD
CY2018Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7543509 shares
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
50000 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12981599 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11888240 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26088820 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11888240 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26088820 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
11888 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2609 USD
CY2017Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
8573861 USD
CY2018Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
5196667 USD
CY2017Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
8329045 USD
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3475 USD
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
159795 USD
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
104706 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
370000 USD
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
75000 USD
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.98
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.133
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.203
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
224900 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1396300 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2377400 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
151800 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3852000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8773000 USD
CY2017 us-gaap Depreciation
Depreciation
5787 USD
CY2018 us-gaap Depreciation
Depreciation
19555 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11605817 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24162279 USD
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3946000 USD
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4921000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2234800 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5074100 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1544300 USD
CY2017 innt Receivable For Warrants Exercised
ReceivableForWarrantsExercised
0.00 USD
CY2018 innt Receivable For Warrants Exercised
ReceivableForWarrantsExercised
87152 USD
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26794534 shares
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.009
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065225 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
697334 USD
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
50000 USD
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
420000 USD
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.025
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.014
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.020
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.000
CY2017Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
0 USD
CY2018Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
370000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7161612 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5162004 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6405225 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4619580 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10664991 USD
CY2018Q2 dei Entity Public Float
EntityPublicFloat
313000000 USD
CY2018 dei Entity Registrant Name
EntityRegistrantName
INNOVATE BIOPHARMACEUTICALS, INC.
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Trading Symbol
TradingSymbol
INNT
CY2018 innt Additional Term Agreed Upon In Severance Agreement
AdditionalTermAgreedUponInSeveranceAgreement
P6M
CY2018 innt Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents
913000 USD
CY2018 innt Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents
913000 USD
CY2017Q4 innt Capital Stock Authorized
CapitalStockAuthorized
250000000 shares
CY2018Q1 innt Capital Stock Authorized
CapitalStockAuthorized
360000000 shares
CY2017 innt Convertible Promissory Notesbeneficial Conversion Feature
ConvertiblePromissoryNotesbeneficialConversionFeature
0 USD
CY2018 innt Convertible Promissory Notesbeneficial Conversion Feature
ConvertiblePromissoryNotesbeneficialConversionFeature
3077887 USD
CY2017 innt Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
83200 USD
CY2018 innt Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
-82300 USD
CY2017 innt Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
-0.007
CY2018 innt Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
0.003
CY2018Q3 innt Estimated Clinical Trial Data Management Fee
EstimatedClinicalTrialDataManagementFee
1100000 USD
CY2018Q1 innt Exchange Ratio In Connection With Merger
ExchangeRatioInConnectionWithMerger
0.37686604
CY2018 innt Fair Value Net Derivative Asset Liability Measuredon Recurring Basis Unobservable Inputs Reconciliation Change In Derivative Liability
FairValueNetDerivativeAssetLiabilityMeasuredonRecurringBasisUnobservableInputsReconciliationChangeInDerivativeLiability
50000 USD
CY2016 innt Milestone Fee Free Sales Target Value
MilestoneFeeFreeSalesTargetValue
1500000000 USD
CY2017 innt Milestoneand Royalty Fee
MilestoneandRoyaltyFee
0 USD
CY2018 innt Milestoneand Royalty Fee
MilestoneandRoyaltyFee
0 USD
CY2018 innt Net Proceeds From Issuance Of Common Stock After Deducting Stock Issuance Costs
NetProceedsFromIssuanceOfCommonStockAfterDeductingStockIssuanceCosts
16500000 USD
CY2017 innt Noncash Accrued Interest Convertedto Convertible Note Payable
NoncashAccruedInterestConvertedtoConvertibleNotePayable
0.00 USD
CY2018 innt Noncash Accrued Interest Convertedto Convertible Note Payable
NoncashAccruedInterestConvertedtoConvertibleNotePayable
156667 USD
CY2017 innt Noncash Additionof Deferred Offering Costs
NoncashAdditionofDeferredOfferingCosts
159795 USD
CY2018 innt Noncash Additionof Deferred Offering Costs
NoncashAdditionofDeferredOfferingCosts
54706 USD
CY2017 innt Noncash Additionof Derivative Liability
NoncashAdditionofDerivativeLiability
0.00 USD
CY2018 innt Noncash Additionof Derivative Liability
NoncashAdditionofDerivativeLiability
420000 USD
CY2017 innt Noncash Deferred Offering Costs Reclassifiedto Additional Paidin Capital
NoncashDeferredOfferingCostsReclassifiedtoAdditionalPaidinCapital
0.00 USD
CY2018 innt Noncash Deferred Offering Costs Reclassifiedto Additional Paidin Capital
NoncashDeferredOfferingCostsReclassifiedtoAdditionalPaidinCapital
159795 USD
CY2018 innt Number Of Warrants Issued
NumberOfWarrantsIssued
1400000 shares
CY2017Q4 innt Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
60000 USD
CY2017Q4 innt Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
CY2018Q4 innt Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
CY2017 innt Payment Of Stock Subscription Receivable
PaymentOfStockSubscriptionReceivable
25 USD
CY2017 innt Paymentof Deferred Equity Issuance Cost
PaymentofDeferredEquityIssuanceCost
0 USD
CY2018 innt Paymentof Deferred Equity Issuance Cost
PaymentofDeferredEquityIssuanceCost
209795 USD
CY2017 innt Payments To Executives
PaymentsToExecutives
145000 USD
CY2018 innt Placement Agent Fees
PlacementAgentFees
1600000 USD
CY2017 innt Proceeds From Rececived Of Payment Of Stock Subscription Receivable
ProceedsFromRececivedOfPaymentOfStockSubscriptionReceivable
25 USD
CY2018 innt Proceeds From Rececived Of Payment Of Stock Subscription Receivable
ProceedsFromRececivedOfPaymentOfStockSubscriptionReceivable
0 USD
CY2017 innt Proceeds From Shortterm Convertible Debt
ProceedsFromShorttermConvertibleDebt
5130000 USD
CY2018 innt Proceeds From Shortterm Convertible Debt
ProceedsFromShorttermConvertibleDebt
345000 USD
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
280394 USD
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
342400 USD
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
333600 USD
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-101000 USD
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
603900 USD
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-157700 USD
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-477200 USD
CY2017 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
0 USD
CY2018 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
224900 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
746797 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86412 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-543000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-441050 USD
CY2017 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2018 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-50000 USD
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
155339 USD
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
298724 USD
CY2017 us-gaap Interest Expense
InterestExpense
436294 USD
CY2018 us-gaap Interest Expense
InterestExpense
6152043 USD
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
396769 USD
CY2017 us-gaap Interest Income Other
InterestIncomeOther
0 USD
CY2018 us-gaap Interest Income Other
InterestIncomeOther
163832 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
280287 USD
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
560380 USD
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
101624 USD
CY2017Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
798489 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6454188 USD
CY2017 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2018 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
978674 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12973103 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10113252 USD
CY2018Q4 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3600000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5130025 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20556610 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38727 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13943 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5096546 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15169330 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-11605817 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-14959744 USD
us-gaap Net Income Loss
NetIncomeLoss
-19175296 USD
us-gaap Net Income Loss
NetIncomeLoss
-19951226 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24162279 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-436294 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5938211 USD
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1496862 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38727 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13943 USD
CY2017 us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
0 USD
CY2018 us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
75000 USD
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5196667 USD
CY2017Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
244816 USD
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
18918000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
128993 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
50000 USD
CY2018Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
11169523 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
18224068 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
11169523 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
11328617 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
14704688 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
14485035 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
18224068 USD
CY2018Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P24M
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
161844 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
504907 USD
CY2017 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
0 USD
CY2018 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
75000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18132661 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18100000 USD
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
182428 USD
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
928178 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40707 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35095 USD
CY2018 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
75000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4007911 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7559077 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19353691 USD
CY2018 us-gaap Severance Costs1
SeveranceCosts1
320000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
6018732 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3805000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61243 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.982
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47300 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34313435 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38528987 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39304917 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43515970 USD
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
5000 USD
CY2017 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.056
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P24M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P21M
CY2017 us-gaap Stock Issued1
StockIssued1
0 USD
CY2018 us-gaap Stock Issued1
StockIssued1
9229819 USD
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
9229819 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16182002 USD
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
182428 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-6587554 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12174614 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3659064 USD
CY2018Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1544300 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4921000 USD
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11888240 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24762151 shares
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject the Company to concentration of credit risk consists of cash and cash equivalents. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the financial institutions. The Company has not experienced any losses on such accounts.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2018 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Liability </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">The Company accounts for derivative instruments in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 815, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative and Hedging, </font><font style="font-family:inherit;font-size:10pt;">which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value. The Company&#8217;s derivative financial instrument consists of an embedded option in the Company&#8217;s convertible debt. The embedded derivative includes provisions that provide the noteholder with certain conversion and put rights at various conversion or redemption values as well as certain call options for the Company. See Note 6&#8212;Debt for further details.</font></div></div>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability, valuation allowance for income tax assets and management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0001551986-19-000019-index-headers.html Edgar Link pending
0001551986-19-000019-index.html Edgar Link pending
0001551986-19-000019.txt Edgar Link pending
0001551986-19-000019-xbrl.zip Edgar Link pending
fig1.jpg Edgar Link pending
fig10.jpg Edgar Link pending
fig11.jpg Edgar Link pending
fig12.jpg Edgar Link pending
fig13.jpg Edgar Link pending
fig14.jpg Edgar Link pending
fig15.jpg Edgar Link pending
fig2.jpg Edgar Link pending
fig3.jpg Edgar Link pending
fig4.jpg Edgar Link pending
fig5.jpg Edgar Link pending
fig6.jpg Edgar Link pending
fig7.jpg Edgar Link pending
fig8.jpg Edgar Link pending
fig9.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
innovatebiopharmalogo1a02.jpg Edgar Link pending
innt-20181231.xml Edgar Link completed
innt-20181231.xsd Edgar Link pending
innt-20181231_cal.xml Edgar Link unprocessable
innt-20181231_def.xml Edgar Link unprocessable
innt-20181231_lab.xml Edgar Link unprocessable
innt-20181231_pre.xml Edgar Link unprocessable
innt1231201810-k.htm Edgar Link pending
inntex10-27laumas.htm Edgar Link pending
inntex10-29priorsep.htm Edgar Link pending
inntex10-30priorconsult.htm Edgar Link pending
inntex10-33almenoffsep.htm Edgar Link pending
inntex23-1mhmconsent.htm Edgar Link pending
inntex3-1certinc.htm Edgar Link pending
inntex31-1.htm Edgar Link pending
inntex31-2.htm Edgar Link pending
inntex32-1.htm Edgar Link pending
inntex32-2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
table1.jpg Edgar Link pending